Earnings ·
Reports Q3 net loss of $111.4M as CASGEVY revenue rises to $99 million
CRSPCRISPR Therapeutics AG
CRISPR Therapeutics reported a third-quarter 2026 net loss of $111.4 million, compared to a $106.4 million loss in the prior-year period. Revenue reached $12.7 million, driven by collaboration revenue of $12.3 million and CASGEVY sales of $99 million, which represented 30% quarter-over-quarter growth. The company holds $2.28 billion in cash and marketable securities. Pipeline updates include FDA RMAT designations for CTX310 and enrollment completion for the Phase 2 trial of CTX611. CRispr Therapeutics is a biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases.